CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related tax sale. On March 14, 2026, 20,625 Restricted Stock Units vested and were converted into 20,625 Common Shares at a conversion price of $0.00 per share.

The vested RSUs are part of an 82,500-share award granted on March 14, 2025, scheduled to vest in four equal annual installments through March 14, 2029. On March 16, 2026, 10,349 Common Shares were sold at $48.26 per share to cover tax withholding obligations under the company’s RSU Settlement Policy, which the footnotes state does not represent a discretionary trade. After these transactions, Kulkarni directly holds 245,834 Common Shares and 61,875 Restricted Stock Units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/14/2026		M(1)		20,625	A	(2)	256,183	D
Common Shares	03/16/2026		S		10,349(3)	D	$48.26	245,834	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/14/2026		M(1)			20,625	(4)	(4)	Common Shares	20,625	(2)	61,875	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. This restricted stock unit award was granted on March 14, 2025 with respect to 82,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CRISPR Therapeutics (CRSP) CEO report?

CRISPR Therapeutics CEO Samarth Kulkarni reported RSU vesting and a related tax sale. 20,625 Restricted Stock Units converted into Common Shares, and 10,349 shares were sold at $48.26 each solely to satisfy tax withholding obligations under the company’s RSU Settlement Policy.

Was the CRSP CEO’s March 2026 share sale a discretionary trade?

No. The filing states the 10,349-share sale was mandated by CRISPR Therapeutics’ RSU Settlement Policy to fund tax withholding on vested RSUs. The footnote clarifies it was executed to cover taxes and “does not represent a discretionary trade” by the CEO.

How many CRISPR Therapeutics shares did the CEO sell and at what price?

Samarth Kulkarni reported selling 10,349 Common Shares of CRISPR Therapeutics at $48.26 per share. According to the footnotes, this transaction was specifically to satisfy tax withholding obligations related to recently vested Restricted Stock Units, not a discretionary portfolio decision.

What RSU vesting occurred for the CRSP CEO in March 2026?

On March 14, 2026, 20,625 Restricted Stock Units vested and converted into an equal number of CRISPR Therapeutics Common Shares at a $0.00 conversion price. These RSUs are part of an 82,500-share award granted March 14, 2025, vesting in four annual installments through 2029.

What are the CRSP CEO’s holdings after the reported Form 4 transactions?

Following the March 2026 transactions, Samarth Kulkarni directly holds 245,834 CRISPR Therapeutics Common Shares and 61,875 Restricted Stock Units. These figures reflect the RSU vesting, the tax-related share sale, and the remaining unvested portion of the March 14, 2025 RSU award.

How is the CRSP CEO’s RSU award structured over time?

The CEO received a Restricted Stock Unit award for 82,500 Common Shares on March 14, 2025. One quarter vests on March 14, 2026, with additional quarters vesting on March 14 of 2027, 2028, and 2029, providing a multi-year, time-based equity compensation schedule.